Covidien to Introduce Its OneShot Renal Denervation System at EuroPCR


May 8, 2012—Covidien (Mansfield, MA) announced that it will introduce its new OneShot renal denervation system at the EuroPCR congress in Paris next week. The OneShot system was developed by Maya Medical (Campbell, CA) and received CE Mark clearance in February 2012.  

According to Covidien, the OneShot system is designed to treat patients with hypertension who are nonresponsive to traditional medical therapy. The system features an irrigated, radiofrequency-based balloon catheter used for targeted ablation of sympathetic nerves located within the adventitia of the renal arteries for the purpose of inhibiting sympathetic nerve pathways that can contribute to the progression of hypertension.  

Covidien also announced the commencement of the post-CE Mark approval clinical trial, RAPID (Rapid Renal Sympathetic Denervation for Resistant Hypertension), which will enroll patients throughout Europe and at a site in New Zealand.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.